ACTL6A Overexpression

CI-VAR-00003211Explore in graph →CIViC 3243

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma2
ACTL6A Overexpression	Cisplatin	Predictive	D	Supports Resistance	4	submitted	EID8977 High expression of ACTL6A has been shown to be associated with resistance to cisplatin in multiple cancer types. In vitro experiments using A549 and H1299 lung cancer cell lines showed that overexpres… (full text at CIViC) PMID 33408251 · Xiao et al., 2021 · Open in CIViC	civic
ACTL6A Overexpression	Cisplatin + PanobinostatCombination	Predictive	D	Supports Sensitivity Response	4	submitted	EID8978 ACTL6A plays a role in DNA damage repair by maintaining integrity of the SWI/SNF complex, and is associated with resistance to cisplatin. Results from cell viability and survival assays showed that tr… (full text at CIViC) PMID 33408251 · Xiao et al., 2021 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Ovarian Neoplasm1
ACTL6A Overexpression	Cisplatin	Predictive	D	Supports Resistance	3	submitted	EID8983 High expression of ACTL6A has been shown to be associated with resistance to cisplatin in multiple cancer types. In vitro experiments using A2780cis ovarian cancer cell line showed that overexpression… (full text at CIViC) PMID 33408251 · Xiao et al., 2021 · Open in CIViC	civic